Inflammatory Bowel Disease: Overview

Slides:



Advertisements
Similar presentations
Welcome to Who Wants to be a Millionaire
Advertisements

The Epidemiology of HIV/AIDS in the Republic of Trinidad/Tobago With special reference to Women and Children Robert K. Lee MB,ChB;MPH.
Mental Mind Gym coming …. 30 Second Challenge - Advanced Additive.
$1 Million $500,000 $250,000 $125,000 $64,000 $32,000 $16,000 $8,000 $4,000 $2,000 $1,000 $500 $300 $200 $100 Welcome.
MICS4 Survey Design Workshop Multiple Indicator Cluster Surveys Survey Design Workshop Questionnaire for Individual Women: Marriage/Union.
Exhibit 1. Nearly Two of Five Young Adults Spent Some Time Uninsured in the Past Year Notes: FPL refers to federal poverty level. Numbers may not sum to.
Measures of disease occurrence T Ancelle / A Bosman / D Coulombier / A Moren / P Sudre / M Valenciano/ P Penttinen Peter Kreidl.
Is there a link between inflammatory bowel disease and the metabolic syndrome? Hester Franks Academic F2 Supervisors Professors Hawkey and Macdonald.
Malaria Figures 3.3 billion people at risk of malaria in billion at high risk (>1 case/1000 population) mainly in the WHO African (49%) and South.
Who Wants To Be A Millionaire? Decimal Edition Question 1.
Implementing NICE guidance
£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.
£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.
Welcome to Who Wants to be a Millionaire
£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.
Welcome to Who Wants to be a Millionaire
Welcome to Who Wants to be a Millionaire
Managing Crohn’s Disease through Nutritional Intervention
Centre for Adolescent Health Global patterns of mortality in young men & women Professor George Patton. Expert Group Meeting on Adolescents, Youth & Development,
$1 Million $500,000 $250,000 $125,000 $64,000 $32,000 $16,000 $8,000 $4,000 $2,000 $1,000 $500 $300 $200 $100 Welcome.
Utredning och diagnostik av PIBD Petter Malmborg ALB.
Making Landmark or Friendly Numbers (Multiplication)
$1 Million $500,000 $250,000 $125,000 $64,000 $32,000 $16,000 $8,000 $4,000 $2,000 $1,000 $500 $300 $200 $100 Welcome.
10 Year Old Topic 2 9 Year Old Topic 4 8 Year Old Topic 5 8 Year Old Topic 6 7 Year Old Topic 7 7 Year Old Topic 8 6 Year Old Topic 9 6 Year Old Topic.
Are You Smarter Than a 5 th Grader? 1,000,000 5th Grade Topic 1 5th Grade Topic 2 4th Grade Topic 3 4th Grade Topic 4 3rd Grade Topic 5 3rd Grade Topic.
Number bonds to 10,
Another Presentation © All Rights Reserved.
Children Aged 5 to
IBD Ulcerative Colitis Crohn’s Disease. IBD  Pathogenesis – genetics +environment (smoking,infection,drugs)  UC –bloody diarrhoea. Exacerbation & remission-50%/yr.
Dalia Munoz.  Its an inflammatory bowel disease (IBD) that causes a long- lasting inflammation in your digestive tract.
By: Boris Eng and Dominic Moscarello Inflammatory Bowel Disease (IBD)
CLINICAL AND ENDOSCOPIC CORRELATION OF INFLAMMATORY BOWEL DISEASE Coordinator: Prof. Univ. Dr. Simona Băţagă Students: Andra Oltean Stoica Ioan Adrian.
Community Medicine V Dr. Mehrdad Askarian MD, MPH Professor of Community Medicine.
Baumgart, D C The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis Dtsch Arztebl Int 2009; 106(8): ; DOI: /arztebl
CHAPTER 19 Inflammatory Bowel Disease Source: Burden of digestive diseases in the United States, NIH Publication No
The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States  Michael D. Kappelman, Sheryl L. Rifas–Shiman,
Clinical Gastroenterology and Hepatology
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Work disability in inflammatory bowel disease
IBD in the elderly population: Results from a population-based study in Western Hungary, 1977���2008  Peter Laszlo Lakatos, Gyula David, Tunde Pandur,
YouTube® and inflammatory bowel disease
Digestive system Made by: Lexus Batton.
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Medical management of inflammatory bowel disease
1 Patient enrollment flow chart.
Serum prohepcidin levels in chronic inflammatory bowel diseases
Mersin University TURKEY
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years  May-Bente Bengtson, Camilla.
IBD Therapies: Guidance for Managed Care Professionals
Volume 142, Issue 1, Pages e42 (January 2012)
Managing IBD in Children
Volume 147, Issue 4, Pages e7 (October 2014)
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Research and Healthcare in Inflammatory Bowel Diseases (1)
Osteoporosis in inflammatory bowel disease
Denise Cabeza Nikki Parks Dr. Brent Polk, Advisor
Volume 152, Issue 1, Pages (January 2017)
Inflammatory Bowel Disease in South Limburg (the Netherlands) 1991–2002: Incidence, diagnostic delay, and seasonal variations in onset of symptoms  Mariëlle.
Volume 142, Issue 1, Pages e42 (January 2012)
Reenu Malhotra, Kevin Turner, Amnon Sonnenberg, Robert M. Genta 
Eligibility criteria for inclusion as an expert Delphi panellist
Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome  Claudia I. Reinders, Max Herulf, Tryggve Ljung,
Meenakshi Bewtra, Chinyu Su, James D. Lewis 
Inflammatory Bowel Disease in African American Children Compared With Other Racial/Ethnic Groups in a Multicenter Registry  Jolanda M. White, Siobhán.
The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States  Michael D. Kappelman, Sheryl L. Rifas–Shiman,
Risk factors for postoperative infection after lower gastrointestinal surgery in patients with inflammatory bowel disease: Findings from a large epidemiological.
Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.
Treating Inflammatory Bowel Disease With Diet: A Taste Test
Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.
Presentation transcript:

Inflammatory Bowel Disease: Overview Inflammatory bowel disease, or IBD, profoundly affects the day-to-day health, quality of life, and prospects for survival of more than 1 million persons in the United States and millions more worldwide. This presentation pays particular attention to IBD in women, in whom this disease requires special consideration.

IBD: Overview Prevalence: ~250 cases per 100,0001 More than 1 million cases estimated in United States1 Ulcerative colitis (UC): 50%1 Crohn’s disease (CD): 50%1 Incidence: 15 cases per 100,0001 Onset: 30% between 10 and 19 years of age2 Young children: <2%2 Peak age of onset: 20s & 30s, again in 60s3 Slightly greater risk for women and elderly4 IBD comprises 2 distinct disease entities: Crohn’s disease, or CD, and ulcerative colitis, or UC. Both of these diseases are heterogeneous inflammatory disorders whose etiology is not fully understood but that result from chronic up-regulation of the enteric mucosal immune system.1 The lesions of CD may appear throughout the gastrointestinal tract, from the mouth to the anus, whereas UC is confined to the large intestine.2,3 Overall, the prevalence of IBD appears to have a bimodal distribution. There are estimated to be more than 1 million cases in the United States, approximately evenly divided between UC and CD.4 Onset is most common in the second and third decades of life, with a second, smaller peak in the sixth decade.5 The incidence of IBD is approximately equal in males and females, with a slightly higher risk for women than for men; males have a 20% higher incidence of UC than females, and females have a 20% higher incidence of CD than males.5 1CCFA Library: Basic Facts. Available at: http://www.ccfa.org. 2Grand RJ, et al. Clin Invest Med. 1996;19:373-380. 3Hanauer SB. Cecil Textbook of Medicine. 20th ed. Philadelphia, Pa: WB Saunders Co; 1996:707. 4Lashner BA. In: Stein SH, Rood RP, eds. Inflammatory Bowel Disease: A Guide for Patients and Their Families. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1999:23-29.

IBD: Overview (cont’d) Scope of disorder (United States) 700,000 physician visits per year 100,000 hospitalizations per year CD accounts for two thirds Long-term outlook Chronic, lifelong disease Acute flare-ups alternating with remission Complications and increased mortality Surgery for 50% to 80% of CD patients The impact of IBD on healthcare is significant. IBD is the reason for 700,000 physician visits and 100,000 hospitalizations each year, two thirds of these being for CD. Both CD and UC are chronic, lifelong diseases characterized by alternating flare-ups and remissions whose management may eventually become more complicated. Over their lifetimes, approximately 50% to 80% of patients with CD will require surgical treatment. Since no definitive cure is currently available for either disease, treatment focuses on symptomatic control and maintaining quality of life.5,6 Calkins BM. Digestive Diseases in the United States: Epidemiology and Impact. Bethesda, Md: National Institutes of Health; 1994.

Empiric Risk for Developing Crohn's Disease (%) Risk for Developing CD 60 50.0 50 40 37.0 Empiric Risk for Developing Crohn's Disease (%) 30 20 16.8 The empiric risk for developing CD based on genetic factors is shown. A child whose parents both have CD has a 50% risk of developing the disease. If one of identical twins has CD, the chance that the other twin will develop the disease is 37%. Among Ashkenazic Jews, if a sibling has the disease, the chance that the other sibling will develop CD is 16.8%. The risk for several other genetic relationships declines below 10%. The risk in the general population is 0.1%.7 10 7.5 7.4 7.0 4.6 <4.0 <0.2 0.1 Offspr Both Parents Sib Ashk Jew Offspr Ashk Jew Sib Non-Jew Heterozygote NOD2 MZ Twin Parent DZ Twin Homozygote NOD2 General Population

IBD: Systemic Complications Growth failure in children Eye inflammation* Lower bone density* Kidney stones Liver and bile duct inflammation Subfertility* Ovaries Uterus Gallstones Patients with IBD frequently suffer from other chronic inflammatory diseases that affect other organ systems. The course of these diseases often runs independently of the course of IBD; however, they occur so frequently in patients with IBD that, rather than being regarded as comorbidities, they are seen as extraintestinal manifestations of the underlying disease. Eye inflammations – iritis and uveitis – were the most common extraintestinal diseases found in a Canadian population-based survey, affecting about twice as many women as men. Primary sclerosing cholangitis was more common among men than among women with UC, as was ankylosing spondylitis. Among skin lesions, pyoderma gangrenosum was equally prevalent in men and women, but erythema nodosum was more common in women than in men. Overall, 6.2% of patients had 1 of those 6 major extraintestinal diseases.14 In some referral centers, however, the reported incidence has been as high as 21% in patients with UC, 42% in those with either UC or Crohn’s colitis, and 23% in those with CD confined to the small bowel.15,16 Additional systemic complications include reduced bone mineral density, or BMD, related to increased bone resorption without an increase in bone formation. This is more prevalent in women than in men and is independent of corticosteroid intake.17 Other extraintestinal manifestations include gallstones, kidney stones, liver inflammation, and arthritis.15 Fourteen percent to 88% of children with IBD are reported to have subnormal growth even before the time of initial diagnosis. Growth retardation may continue because of both malabsorption and reduced nutritional intake and because of growth-suppressing drugs such as corticosteroids.18 Arthritis and joint pains Skin lesions *Higher incidence in women.

Influence of Gender on Illness-Related Concerns in IBD Study of 343 men and women Women report higher levels of symptom severity (P=.04) Higher levels of rating of IBD patient concerns (P<.001) A study of 343 men and women using an instrument designed to identify the differences between the concerns of female and male patients with IBD reported that women noted significantly higher levels of symptom severity. Women’s levels of concern with IBD were much higher than those of men.8 Maunder R, et al. Can J Gastroenterol. 1999;13:728-732.

Patients’ Concerns in IBD Greater in Women Than in Men Feelings about body Attractiveness Feeling alone Having children Intimacy (CD) Sexual performance (CD) Independent of Gender Energy level Medication effects Uncertain nature of IBD Having surgery Having ostomy bag Reaching full potential Being a burden This table lists concerns relating to IBD that were felt more strongly by women than by men and those in which sex differences did not matter. Those felt more intensely by women included feelings about their bodies, a loss in sense of attractiveness, feeling alone, and concern about having children and, for women with CD but not UC, about intimacy and sexual performance. With regard to sexual performance, men with UC reported slightly greater levels of concern than did women. However, women with CD had much higher levels of concern about sexual performance than did men.8 A study using the Rating Form of IBD Patient Concerns reported that women had higher levels of concern in all 4 indices used – impact of disease, sexual intimacy, complication, and body stigma. It was suggested that the differences for sexual intimacy and disease complications were largely explained by differences in disease severity.9 All patients, regardless of sex, are concerned with loss of energy, the effects of medications, the possibility of surgery, and the issue of being a burden to caregivers. Aside from the gender differences, there are important differences in the concerns of CD and UC patients. Because of the increased likelihood that they will develop cancer (the cumulative incidence of colorectal cancer in patients with pancolitis over 35 years is as high as 25%), that particular eventuality ranked high among the concerns of UC patients. In patients with CD, the chief concern was the uncertain nature of their disease, likely owing to the frequency of recurrences and flare-ups.3,9,10 Maunder R, et al. Can J Gastroenterol. 1999;13:728-732.

Gender-Related Considerations in IBD Women Men Reproductive issues  fertility after IPAA or proctocolectomy  risk of relapse if disease active at time of conception fertility with sulfasalazine Sperm count with methotrexate Disease-related concerns  concern re: body stigma, loss of bowel control — Sexuality  sexual activity because of dyspareunia, abdominal pain, etc  libido and sexual satisfaction after proctocolectomy Fertility in women may be affected by surgery, including ileal pouch-anal anastomosis, or IPAA. If women are in the active disease state at the time of conception, there is an increased risk of relapse. For men, the only comparable concern is with sperm viability when taking sulfasalazine.11 Questions have been raised about the impact of 6-mercaptopurine – 6-MP – on male fertility, although the sperm quality is normal.12,13 As stated earlier, women have a higher level of disease-related concerns, primarily because of greater disease severity. Finally, sexual activity is more affected in women than in men. Women are more subject to pain during intercourse, and men may experience a postsurgical decline in libido.

The Effect of Smoking on Crohn’s Disease in Women There are now two studies that have specifically addressed the gender effect of tobacco Women smokers undergoing surgery are 5 times more likely to have a recurrence than a non-smoker, and recur more quickly1 Women smokers hastened onset of disease and increased the need for immunomodulators2 1Kane SV, Gastroenterol 2002; 124(5):A1169 2 Cosnes J Clin Gastro and Hepatol 2004;2:41-48.